Developer docs
API playgroundTry for free, no card

Search company profiles

Neuromod Devices

Full company profile

uuid0000g4s

Namestring
Neuromod Devices
Legal namestring
Neuromod Devices Ltd
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Neuromod Devices Ltd is an Irish medical technology company headquartered in Dublin that has developed Lenire, the first and only FDA-approved bimodal neuromodulation device for the treatment of tinnitus. Lenire combines simultaneous auditory stimulation via headphones with gentle electrical stimulation of the tongue to induce neuroplastic changes in the brain, with clinical evidence showing clinically significant symptom reduction in 81.8–91.5% of treated patients across trials and real-world cohorts involving 600+ subjects, supported by 136+ patents across 37 countries.

The company operates a single-product business model: it manufactures and sells the Lenire hardware device and associated treatment protocols exclusively through a certified network of audiology and ENT clinics. As of 2026, Lenire is available in more than 130 clinics staffed by over 200 clinicians across the USA, Europe, and newly launched Canada, with planned Australian entry in Q4 2026 and additional European launches in the Netherlands and Portugal. Revenue is generated through hardware sales to clinic partners, with the company providing clinical training, commercial enablement, and an all-in-one Partner Platform to support practice economics.

Neuromod has raised approximately €40 million across multiple rounds since 2010, with key institutional backers including Panakès Partners, Fountain Healthcare Partners, the European Investment Bank, and Enterprise Ireland. The company has scaled through a tightly executed regulatory-first strategy — FDA De Novo approval (March 2023), CE-Mark, Health Canada, ISO 13485, and TGA clearance — and is now in active commercial expansion across North America, Europe, and Oceania, supported by a lean 11–50 employee organization and a distributed commercial leadership team including a dedicated President of Global Commercial Operations and CEO of Neuromod USA.

Short descriptiontext

Neuromod Devices is an Irish medtech company that develops and commercializes Lenire, the first FDA-approved bimodal neuromodulation device for tinnitus, sold through a certified network of audiology clinics across the US, Europe, and Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tinnitus treatment devices, bimodal neuromodulation therapy, auditory nerve stimulation, neurostimulation medical devices, audiology clinical equipment
Industry1 code
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neuromodulation medical devices for tinnitus treatment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Lenire Tinnitus Treatment Device Sales
TypeHardware Sales
Description

Neuromod generates revenue from the sale and distribution of its Lenire tinnitus treatment device through certified clinical providers and clinic partners across the USA, Europe, and Canada. The device is provided to tinnitus patients via clinical settings with supporting treatment protocols.

neuromod.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Lenire
Description

FDA-approved bimodal neuromodulation tinnitus treatment device that combines auditory and tongue stimulation to provide treatment for tinnitus patients.

neuromod.com
Core offering1 text field

Neuromod Devices develops, manufactures, and distributes Lenire, the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. Lenire combines simultaneous auditory stimulation through headphones and gentle electrical stimulation to the tongue via a proprietary mouthpiece to deliver a 12-week at-home treatment protocol prescribed and supervised by trained audiologists at certified tinnitus treatment clinics. The company sells the device and associated Partner Platform support services to clinics rather than directly to consumers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 81.8% of 140 patients experienced clinically significant tinnitus reduction after 12 weeks of Lenire treatment
+3 more records
Product overview1 text field

Neuromod Devices offers a single unified core product, Lenire, which is the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. The device combines auditory stimulation through headphones with gentle tongue stimulation via a proprietary tongue tip to treat tinnitus. Lenire is supported by the largest body of evidence for any tinnitus-specific medical device, with over 136 neuromodulation patents across 37 countries and distribution through more than 130 clinics in the USA and Europe. The company provides an end-to-end Partner Platform for clinics that includes practice enablement, clinical and commercial training, and scalable onboarding support.

Product and service2 records
1Lenire Tinnitus Treatment Device
CategoryTinnitus treatment medical device
Description

Lenire is the first and only FDA-approved bimodal neuromodulation device for tinnitus, combining simultaneous auditory stimulation via headphones and gentle tongue stimulation via a proprietary intra-oral tip. It is prescribed and supervised by trained audiologists at certified tinnitus treatment clinics as a 12-week at-home treatment course for adults with bothersome tinnitus. It is supported by three large-scale peer-reviewed clinical trials involving more than 600 patients.

2Tinnitus Masterclass Online Course
CategoryClinical education and training services
Description

An online educational course developed by Neuromod for audiologists and ENT specialists in Europe that combines medical, clinical, and commercial modules on tinnitus care, with the goal of expanding the pool of clinicians able to deliver Lenire treatment.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

KPMG is listed as a partner on Neuromod's website, suggesting professional services or advisory support for the company's operations.

2BSI
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

BSI (British Standards Institution) is listed as a partner, likely providing ISO certification and quality management standards support for Lenire's regulatory compliance.

neuromod.com
3Tomkins
Strategic tierMinorTypeOthers
Description

Tomkins is listed as a partner logo on Neuromod's website, potentially providing legal or advisory services.

neuromod.com
Strategic tierMinorTypeOthers
Description

Shay Glenn is listed as a partner logo on Neuromod's website, potentially providing legal or advisory services.

5Byrne Wallace
Strategic tierMinorTypeOthers
Description

Byrne Wallace is listed as a partner logo on Neuromod's website, potentially providing legal advisory services for the Irish-headquartered company.

neuromod.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian medical device company that pioneered the Oasis tinnitus treatment device using customized acoustic stimulation; one of the closest direct competitors to Lenire in the clinic-delivered, device-based tinnitus treatment category.

TypeDirect peer
Description

Developer of the Levo tinnitus sound therapy system, a FDA-cleared personalized sound therapy device delivered through audiologists; competes with Lenire for the same clinician channel and tinnitus patient population.

3SoundCure (StimRouter / Serenade)
TypeDirect peer
Description

Developed the Serenade tinnitus treatment device using custom sound therapy; another clinic-administered, FDA-cleared tinnitus therapy competing for the same audiologist customer base as Lenire.

TypeEmerging player
Description

Markets Desyncra for tinnitus, a CR(r) neuromodulation therapy that pairs acoustic stimulation with electrical tongue stimulation, making it the closest mechanistic competitor to Lenire's bimodal neuromodulation approach.

TypeBroad incumbent
Description

Global hearing aid leader whose Phonak brand offers tinnitus balance programs and sound therapy features integrated into hearing aids; competes via scale, audiologist relationships, and bundled solutions rather than dedicated tinnitus devices.

TypeBroad incumbent
Description

Owns the Widex and Signia hearing aid brands, both of which offer integrated tinnitus therapy features; represents a broad incumbent alternative that audiologists can choose instead of a dedicated tinnitus device like Lenire.

TypeBroad incumbent
Description

Major hearing aid manufacturer whose ReSound and Beltone brands include tinnitus sound therapy features and apps, providing an alternative path for tinnitus care within mainstream hearing aid fitting.

TypeBroad incumbent
Description

US-based hearing aid manufacturer offering tinnitus technology within its hearing aid lineup and patient apps, competing with Lenire for the same tinnitus-patient demand via existing hearing care channels.

TypeRegional player
Description

Australian-headquartered implantable hearing solutions company with growing tinnitus and hearing loss adjacencies; relevant as a regional peer given Neuromod's Australian expansion plans.

10Cogito (behavioral health / digital therapeutics)
TypeOthers
Description

While not a direct tinnitus competitor, behavioral and digital therapeutics for tinnitus (e.g., CBT-based apps) represent a non-device alternative category that audiologists and patients may choose instead of a clinic-based neuromodulation device.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuromod Devices

Neuromodulation medical devices for tinnitus treatmentneuromoddevices.com

Neuromod Devices is an Irish medtech company that develops and commercializes Lenire, the first FDA-approved bimodal neuromodulation device for tinnitus, sold through a certified network of audiology clinics across the US, Europe, and Canada.

What Neuromod Devices does

Neuromod Devices Ltd is an Irish medical technology company headquartered in Dublin that has developed Lenire, the first and only FDA-approved bimodal neuromodulation device for the treatment of tinnitus. Lenire combines simultaneous auditory stimulation via headphones with gentle electrical stimulation of the tongue to induce neuroplastic changes in the brain, with clinical evidence showing clinically significant symptom reduction in 81.8–91.5% of treated patients across trials and real-world cohorts involving 600+ subjects, supported by 136+ patents across 37 countries.

The company operates a single-product business model: it manufactures and sells the Lenire hardware device and associated treatment protocols exclusively through a certified network of audiology and ENT clinics. As of 2026, Lenire is available in more than 130 clinics staffed by over 200 clinicians across the USA, Europe, and newly launched Canada, with planned Australian entry in Q4 2026 and additional European launches in the Netherlands and Portugal. Revenue is generated through hardware sales to clinic partners, with the company providing clinical training, commercial enablement, and an all-in-one Partner Platform to support practice economics.

Neuromod has raised approximately €40 million across multiple rounds since 2010, with key institutional backers including Panakès Partners, Fountain Healthcare Partners, the European Investment Bank, and Enterprise Ireland. The company has scaled through a tightly executed regulatory-first strategy — FDA De Novo approval (March 2023), CE-Mark, Health Canada, ISO 13485, and TGA clearance — and is now in active commercial expansion across North America, Europe, and Oceania, supported by a lean 11–50 employee organization and a distributed commercial leadership team including a dedicated President of Global Commercial Operations and CEO of Neuromod USA.

Neuromod Devices firmographics

Firmographics
Name
Neuromod Devices
Legal name
Neuromod Devices Ltd
Website
https://neuromoddevices.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Neuromod Devices is an Irish medtech company that develops and commercializes Lenire, the first FDA-approved bimodal neuromodulation device for tinnitus, sold through a certified network of audiology clinics across the US, Europe, and Canada.
Ownership category
akta.pro rank

Neuromod Devices industry classification

Industry
Product category
Neuromodulation medical devices for tinnitus treatment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Tinnitus treatment devices
  • Bimodal neuromodulation therapy
  • Auditory nerve stimulation
  • Neurostimulation medical devices
  • Audiology clinical equipment

Where Neuromod Devices is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

Neuromod Devices business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Lenire Tinnitus Treatment Device Sales: Neuromod generates revenue from the sale and distribution of its Lenire tinnitus treatment device through certified clinical providers and clinic partners across the USA, Europe, and Canada. The device is provided to tinnitus patients via clinical settings with supporting treatment protocols.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Neuromod Devices product offering

Product offering

Core offering

Neuromod Devices develops, manufactures, and distributes Lenire, the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. Lenire combines simultaneous auditory stimulation through headphones and gentle electrical stimulation to the tongue via a proprietary mouthpiece to deliver a 12-week at-home treatment protocol prescribed and supervised by trained audiologists at certified tinnitus treatment clinics. The company sells the device and associated Partner Platform support services to clinics rather than directly to consumers.

Product overview

Neuromod Devices offers a single unified core product, Lenire, which is the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. The device combines auditory stimulation through headphones with gentle tongue stimulation via a proprietary tongue tip to treat tinnitus. Lenire is supported by the largest body of evidence for any tinnitus-specific medical device, with over 136 neuromodulation patents across 37 countries and distribution through more than 130 clinics in the USA and Europe. The company provides an end-to-end Partner Platform for clinics that includes practice enablement, clinical and commercial training, and scalable onboarding support.

Differentiator

Problem solved

Functional benefit

Brands

  • Lenire: FDA-approved bimodal neuromodulation tinnitus treatment device that combines auditory and tongue stimulation to provide treatment for tinnitus patients.

Products and services

  • Lenire Tinnitus Treatment Device Lenire is the first and only FDA-approved bimodal neuromodulation device for tinnitus, combining simultaneous auditory stimulation via headphones and gentle tongue stimulation via a proprietary intra-oral tip. It is prescribed and supervised by trained audiologists at certified tinnitus treatment clinics as a 12-week at-home treatment course for adults with bothersome tinnitus. It is supported by three large-scale peer-reviewed clinical trials involving more than 600 patients.
  • Tinnitus Masterclass Online Course An online educational course developed by Neuromod for audiologists and ENT specialists in Europe that combines medical, clinical, and commercial modules on tinnitus care, with the goal of expanding the pool of clinicians able to deliver Lenire treatment.

Quantifiable outcome

  • 81.8% of 140 patients experienced clinically significant tinnitus reduction after 12 weeks of Lenire treatment
  • +3 more outcomes

Companies that use Neuromod Devices

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Neuromod Devices technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Neuromod Devices partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered supporting and minor.

  • KPMGsupportingImplementation/ SI/ Consulting PartnerKPMG is listed as a partner on Neuromod's website, suggesting professional services or advisory support for the company's operations.
  • BSIsupportingImplementation/ SI/ Consulting PartnerBSI (British Standards Institution) is listed as a partner, likely providing ISO certification and quality management standards support for Lenire's regulatory compliance.
  • TomkinsminorOthersTomkins is listed as a partner logo on Neuromod's website, potentially providing legal or advisory services.
  • Shay GlennminorOthersShay Glenn is listed as a partner logo on Neuromod's website, potentially providing legal or advisory services.
  • Byrne WallaceminorOthersByrne Wallace is listed as a partner logo on Neuromod's website, potentially providing legal advisory services for the Irish-headquartered company.

Scale indicators8 records

Recent moves9 records

Expansion highlights7 records

Neuromod Devices competitors and assessment

Company assessment

Direct peers

  • Neuromonics: Australian medical device company that pioneered the Oasis tinnitus treatment device using customized acoustic stimulation; one of the closest direct competitors to Lenire in the clinic-delivered, device-based tinnitus treatment category.
  • Otoharmonics (Levo System): Developer of the Levo tinnitus sound therapy system, a FDA-cleared personalized sound therapy device delivered through audiologists; competes with Lenire for the same clinician channel and tinnitus patient population.
  • SoundCure (StimRouter / Serenade): Developed the Serenade tinnitus treatment device using custom sound therapy; another clinic-administered, FDA-cleared tinnitus therapy competing for the same audiologist customer base as Lenire.

Emerging players

  • Desyncra: Markets Desyncra for tinnitus, a CR(r) neuromodulation therapy that pairs acoustic stimulation with electrical tongue stimulation, making it the closest mechanistic competitor to Lenire's bimodal neuromodulation approach.

Broad incumbents

  • Sonova (Phonak): Global hearing aid leader whose Phonak brand offers tinnitus balance programs and sound therapy features integrated into hearing aids; competes via scale, audiologist relationships, and bundled solutions rather than dedicated tinnitus devices.
  • WS Audiology (Widex / Signia): Owns the Widex and Signia hearing aid brands, both of which offer integrated tinnitus therapy features; represents a broad incumbent alternative that audiologists can choose instead of a dedicated tinnitus device like Lenire.
  • GN Hearing (ReSound / Beltone): Major hearing aid manufacturer whose ReSound and Beltone brands include tinnitus sound therapy features and apps, providing an alternative path for tinnitus care within mainstream hearing aid fitting.
  • Starkey Hearing Technologies: US-based hearing aid manufacturer offering tinnitus technology within its hearing aid lineup and patient apps, competing with Lenire for the same tinnitus-patient demand via existing hearing care channels.

Regional players

  • Cochlear Limited: Australian-headquartered implantable hearing solutions company with growing tinnitus and hearing loss adjacencies; relevant as a regional peer given Neuromod's Australian expansion plans.

Others

  • Cogito (behavioral health / digital therapeutics): While not a direct tinnitus competitor, behavioral and digital therapeutics for tinnitus (e.g., CBT-based apps) represent a non-device alternative category that audiologists and patients may choose instead of a clinic-based neuromodulation device.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Neuromod Devices social profiles

Digital presence

Neuromod Devices compliance and trust

Trust signal

Compliance3 records

Neuromod Devices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuromod Devices leadership team

Management profile

Number of profiles

Profiles7 records

Neuromod Devices funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuromod Devices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuromod Devices

What does Neuromod Devices do?

Neuromod Devices develops, manufactures, and distributes Lenire, the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. Lenire combines simultaneous auditory stimulation through headphones and gentle electrical stimulation to the tongue via a proprietary mouthpiece to deliver a 12-week at-home treatment protocol prescribed and supervised by trained audiologists at certified tinnitus treatment clinics. The company sells the device and associated Partner Platform support services to clinics rather than directly to consumers.

Is Neuromod Devices a public or private company?

Neuromod Devices is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neuromod Devices founded?

Neuromod Devices was founded in 2010. It employs 51 to 100 people.

Where is Neuromod Devices based?

Neuromod Devices is headquartered in Dublin, Ireland, in the Europe region.

How does Neuromod Devices make money?

One revenue line is on record: lenire Tinnitus Treatment Device Sales.

Who are Neuromod Devices's main competitors?

Direct peers on record are Neuromonics, Otoharmonics (Levo System) and SoundCure (StimRouter / Serenade). Desyncra is listed as an emerging player. Broad incumbents are Sonova (Phonak), WS Audiology (Widex / Signia), GN Hearing (ReSound / Beltone) and Starkey Hearing Technologies. Cochlear Limited is listed as a regional player. Cogito (behavioral health / digital therapeutics) is listed as an others.

Does Neuromod Devices have an API?

No public API is recorded for Neuromod Devices.

What industry is Neuromod Devices in?

Neuromod Devices's product category is Neuromodulation medical devices for tinnitus treatment. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireLenire Tinnitus Device Joins U.S. ENT Guidelines as an Option Doctors May Offer for Bothersome RingingThe American Academy of Otolaryngology-Head and Neck Surgery Foundation updated its tinnitus guideline on Oct. 12, adding Lenire's bimodal neuromodulation as an option clinicians may offer. The guideline grades it as an option, not a first-line treatment, and a company-sponsored trial reported 70.5% of patients with moderate or worse tinnitus improved after six weeks. Long-term durability and independent trials remain uncertain.FinanzNachrichten.deEQS-News: Neuromod Devices: Lenire nun in den klinischen Praxisleitlinien der US-amerikanischen HNO-Gesellschaft aufgenommen - erste neue Behandlungsmethode, die von der American Academy of OtolaryngoThe American Academy of Otolaryngology added Lenire, a bimodal neuromodulation device, to its Tinnitus clinical practice guidelines. It is the only new treatment recommendation since 2014 and the first FDA-approved device for this purpose. The company plans to publish more real-world data to establish it as a leading standard.PR NewswireNew Senior Commercial Appointments at NeuromodNeuromod appointed Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development. Ghiz brings experience from Align Technology and Johnson & Johnson, while Basham previously led audiology at Sonova. The appointments aim to expand access to Lenire, a tinnitus treatment device.Mirage NewsLenire Debuts in Australia to Tackle Tinnitus CrisisNeuromod Devices launched Lenire, a bimodal neuromodulation tinnitus treatment device, in Australia after TGA approval. The device showed 84% sustained relief in two trials and 91.5% meaningful relief in real-world patients. It is now available in Australian clinics following a suitability assessment.PR NewswireAmerican Tinnitus Association Establishes ATA Academy to Close Critical Gap in Tinnitus Provider EducationThe American Tinnitus Association (ATA) announced the establishment of ATA Academy, an online education platform for tinnitus care providers launching in early 2027, designed to address the critical gap in tinnitus provider education. The initiative is supported by a $140,000 lead gift from Neuromod Devices, Ltd., the Irish company behind the Lenire bimodal neuromodulation device. The Academy will offer evidence-based courses, masterclasses, and stackable digital badges to train both new and experienced clinicians in tinnitus assessment, counseling, and management.MorningstarAmerican Tinnitus Association Establishes ATA Academy to Close Critical Gap in Tinnitus Provider EducationThe American Tinnitus Association announced ATA Academy, an online education platform for tinnitus providers, to address the lack of provider training. The platform will launch in early 2027, supported by a $140,000 lead gift from Neuromod Devices. It aims to standardize care for the 50 million U.S. patients affected by tinnitus.PR NewswireLenire Tinnitus Treatment Device Now Available in CanadaNeuromod Devices has launched its Lenire tinnitus treatment device in Canada, making it available through 21 clinics across multiple provinces. The device, proven effective in clinical trials, combines electrical stimulation via the tongue with auditory stimulation to provide long-term relief from tinnitus.NewswireLenire Tinnitus Treatment Device Now Available in CanadaNeuromod Devices has launched its Lenire tinnitus treatment device in Canada through 21 hearing care clinics across five provinces, marking the device's first availability in the country following Health Canada authorization in late 2025. The bimodal neuromodulation device, which uses tongue stimulation paired with auditory therapy, demonstrated 84% sustained tinnitus relief over 12 months across large-scale clinical trials and received US FDA De Novo approval in 2023. The company plans further expansion throughout Canada in 2026 and is partnering with leading tinnitus care clinics including Hearing Solutions to meet demand from the estimated 9.2 million Canadians who experienced tinnitus in the past year.MorningstarLenire Tinnitus Treatment Device Now Available in CanadaNeuromod Devices has launched its Lenire tinnitus treatment device in Canada through 21 clinics across Alberta, British Columbia, Manitoba, Ontario, and Quebec, following Health Canada authorization in late 2025. The bimodal neuromodulation device, which was the first to receive FDA De Novo approval in 2023, uses tongue stimulation combined with auditory tones to provide long-term tinnitus relief, with clinical trials showing 84% of patients sustained relief for at least 12 months. The company reports that 43% of Canadians have experienced tinnitus in their lifetime, representing approximately 11.2 million people, and expansion to additional Canadian clinics is planned throughout 2026.openPR.comOutlook for the Tinnitus Medical Devices Market: Major Segments, Strategic Developments, and Leading CompaniesThe tinnitus medical devices market is projected to grow to $2.32 billion by 2030, driven by rising demand for personalized therapies, digital health adoption, and wearable neuromodulation tools. In April 2024, Italy-based Amplifon S.p.A. acquired U.S. companies Hearing Instruments Inc. and Precision Hearing Aid LLC to expand its retail footprint in the U.S. hearing care market. In December 2024, the Indian Institute of Technology Bombay introduced a cost-efficient tinnitus diagnostic and management device aimed at improving accessibility in low-income regions.